舒洛地特联合厄贝沙坦对老年高血压肾损害患者肾功能及蛋白尿的影响  

Effects of sulodexide plus irbesartan on renal function and uric protein in hypertensive patients with renal impairment

作　　者：王丽丽[1] 余惠珍[1] 王大海[1] 洪富源[1] 

机构地区：[1]福建医科大学省立临床医学院,福州350001

出　　处：《福建医药杂志》2014年第3期8-10,共3页Fujian Medical Journal

摘　　要：目的观察舒洛地特联合厄贝沙坦治疗对高血压肾损害患者肾功能和尿蛋白的影响。方法将66例高血压肾损害患者进行基础治疗后,随机分为,治疗组33例:舒洛地特+厄贝沙坦组(口服厄贝沙坦150mg/d+口服舒洛地特250LSU/次,2次/d);对照组33例:厄贝沙坦组(口服厄贝沙坦150mg/d)。治疗时间12周。观察两组治疗前后的血压、血肌酐、血清光抑素C、尿微量清蛋白、尿α1微球蛋白、尿β2-微球蛋白指标的变化。结果两组血肌酐值治疗前后比较的差异均无统计学意义(P>0.05);两组血清光抑素C、尿微量清蛋白、尿α1微球蛋白及尿β2-微球蛋白值治疗前后比较均有降低,且治疗组降低更加明显(P<0.01)。结论舒洛地特联合厄贝沙坦治疗较单纯应用厄贝沙坦能够更有效地降低高血压肾损害患者的蛋白尿水平,对肾脏具有良好的保护作用。Objective To observe the effects of the combination therapy of sulodexide and irbesartan on renal function and uric protein in hypertensive patients with renal impairment.Methods In total,66senile hypertensive patients with renal impairment were randomly divided into control group（n=33,routine treated with irbesartan 150mg/d）and combined treatment group（n=33,routine treated with sulodexide 250LSU,bid and irbesartan 150mg/d）.After 12weeks,blood pressure,serum creatinine,cystatin C,urine microalbumin,α1-microglobulin and urineβ2-microglobulin were measured and compared between the two groups.Results Compared with those before the study,there were no significantly changes in erumcreatinine at the end of the treatment in both groups（P〉0.05）,but levels of cystatin C were decreased drastically（P〈0.01）;levels of urine microalbumi,α1-microglobulin and urineβ2-microglobulin,were reduced obviously（P〈0.01）,and the reductions of combined treatment group were more evident（P〈0.01）.Conclusion Sulodexide combined with irbesartan,compared with irbesartan alone,can more effectively lower proteinuria level and protect renal function of senile hypertensive patients.

关 键 词：舒洛地特 厄贝沙坦 高血压 肾损害 

分 类 号：R544.1[医药卫生—心血管疾病] R322.61[医药卫生—内科学]